Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

Fig. 1

Study design. Randomization, the primary vaccination phase, the initial antibody persistence phase (Years 1–5), the current long-term persistence phase (Years 7–10)*, and the booster dosing phase are shown. MenACWY meningococcal A, C, W, Y, PS polysaccharide, TT tetanus toxoid

*Study visits for Year 6 of the persistence phase were not conducted due to delay in study approval

Back to article page